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Abstract
Low vitamin D level in HIV-positive persons has been associated with disease progression. We compared the levels of serum
25-hydroxyvitamin D (25(OH)D) in HIV-positive and HIV-negative persons, and investigated the role of nutritional supplementation and
antiretroviral treatment (ART) on serum 25(OH)D levels. A randomised nutritional supplementation trial was conducted at Jimma University
Specialized Hospital, Ethiopia. The trial compared 200 g/d of lipid-based nutrient supplement (LNS) with no supplementation during the
first 3 months of ART. The supplement provided twice the recommended daily allowance of vitamin D (10 μg/200 g). The level of serum
25(OH)D before nutritional intervention and ART initiation was compared with serum 25(OH)D of HIV-negative individuals. A total of
348 HIV-positive and 100 HIV-negative persons were recruited. The median baseline serum 25(OH)D level was higher in HIV-positive
than in HIV-negative persons (42·5 v. 35·3 nmol/l, P< 0·001). In all, 282 HIV-positive persons with BMI> 17 kg/m2 were randomised to
either LNS supplementation (n 189) or no supplementation (n 93) during the first 3 months of ART. The supplemented group had a 4·1
(95% CI 1·7, 6·4) nmol/l increase in serum 25(OH)D, whereas the non-supplemented group had a 10·8 (95% CI 7·8, 13·9) nmol/l decrease in
serum 25(OH)D level after 3 months of ART. Nutritional supplementation that contained vitamin D prevented a reduction in serum
25(OH)D levels in HIV-positive persons initiating ART. Vitamin D replenishment may be needed to prevent reduction in serum 25(OH)D
levels during ART.
Key words: HIV: Vitamin D: Nutritional intervention: Antiretroviral treatment
Vitamin D status is influenced by a variety of factors including
diet, sunlight exposure and underlying health conditions(1).
In HIV-positive individuals, a high frequency of hypovitami-
nosis D has been reported, not only among populations at high
latitudes but also among people living closer to the equator(2–6).
Vitamin D is an immunoregulatory hormone, and vitamin D
deficiency and insufficiency in HIV-positive patients have been
associated with clinical disease progression, treatment
failure and mortality(7–9). Only a few studies have compared the
vitamin D status of HIV-positive with HIV-negative indivi-
duals(4,10,11). Most previous vitamin D studies in HIV-positive
patients are observational, and associations are based on a
single measurement per patient. Moreover, only a few studies
in HIV-positive patients have addressed the effect of vitamin D
supplementation through a nutritional intervention trial with a
placebo- or non-supplemented control group(12,13).
In this trial, a lipid-based nutrient supplement (LNS) containing
twice the daily recommended intake of vitamin D(14) was pro-
vided daily for 3 months to HIV patients initiating antiretroviral
treatment (ART). We measured serum 25-hydroxyvitamin D
(25(OH)D) before and 3 months after initiation of ART. We
compared the level of serum 25(OH)D in HIV-positive and
HIV-negative persons and investigated the role of nutritional
supplementation and ART on serum 25(OH)D levels.
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; ART, antiretroviral treatment; CRP, C-reactive protein; IQR, interquartile range; LNS, lipid-based nutrient
supplement; TB, tuberculosis.
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Methods
Study design and setting
A randomised nutritional supplementation trial was conducted
in Jimma, south-west Ethiopia. The trial compared 200 g/d of
LNS with either whey (LNS/w) or soya (LNS/s) protein with no
supplementation during the first 3 months of ART. Both LNS/w
and LNS/s provided 10 μg/d vitamin D3, which corresponds to
twice the daily recommended intake. The details of the trial
design and methods of recruitment have been described else-
where(14). For the purpose of this study, those randomised to
either LNS/w or LNS/s were categorised as supplemented and
compared with non-supplemented participants.
Participants
HIV patients who were eligible for ART at Jimma University
Specialized Hospital (JUSH), Jimma Health Centre and Agaro
Health Centre were invited to participate in the trial from July
2010 to August 2012(14). Patients who were ≥18 years of age,
not pregnant or lactating, having a BMI> 16 kg/m2 with no
current use of nutritional supplements and living within 50 km
of the recruitment sites were enrolled to the trial. HIV patients
who were not included in the trial because of low BMI were
included in the baseline analysis of serum 25(OH)D. HIV
patients with BMI of 16–17 kg/m2 received supplementation in
the first 3 months, whereas participants with BMI> 17 kg/m2
were randomised to early or delayed nutritional supplementa-
tion. The effect of nutritional supplementation was only asses-
sed among HIV patients with BMI> 17 kg/m2, as they were
randomised to supplementation or no supplementation for
the first 3 months. The HIV-negative reference group, age
≥18 years with no known acute or chronic diseases and
matched for sex, age (± 3 years) and BMI to the last 100
included HIV patients, were recruited among confirmed
HIV-negative individuals from the voluntary counselling and
testing service at JUSH.
Demographic and clinical data
Demographic data were collected using structured ques-
tionnaires in the local languages Amharic or Afaan Oromoo by
trained study nurses. The Household Food Insecurity Access
Scale with questions about experience of food insecurity in the
previous 1 month was used to assess and categorise participants
as food secure as well as mild, moderate and severe food
insecure(15). This scale has previously been validated in
Ethiopia by other investigators(16). Clinical data were collected by
health professionals working in the ART clinics. Patients were
considered tuberculosis (TB) co-infected if they were diagnosed
with TB or were receiving TB treatment at study inclusion.
Body composition
Weight and height were measured with calibrated scales and
stadiometers, respectively, with the participant barefoot
and wearing minimal clothing; BMI was calculated as weight
(kg)/(height (m))2. Body composition was assessed using the
2H dilution method. After collection of pre-dose saliva samples,
30 g of deuterium oxide (99·8% 2H; Sercon) weighed with
0·01 g precision was given orally(17). Post-dose saliva samples
were collected after 4 h of equilibration. Saliva enrichment of 2H
was determined by Fourier Transform Infrared Spectrometry
(IRAffinity-1; Shimadzu). Total body water was calculated from
post-dose 2H enrichment with adjustment for pre-dose enrich-
ment, using a factor of 1·041 to adjust for proton exchange.
Lean body mass was calculated on the basis of an assumed
hydration factor of 73·2%(17).
Laboratory
Laboratory personnel collected 10ml of fasting venous blood in
EDTA tubes, and 10ml in plain tubes at 0 and 3 months. Next,
1ml of whole blood from the EDTA blood collection tubes was
transferred to small tubes, and CD4+ T cells were enumerated
using the Facscount® (Becton-Dickinson). After centrifugation,
serum or plasma was separated and transferred to cryotubes in
aliquots of 1ml and stored at −80°C. Samples were shipped to
the International Clinical laboratory in Addis Ababa, Ethiopia,
for viral load quantification and to Denmark for analysis of
C-reactive protein (CRP) and 25(OH)D, at University of
Copenhagen and Aalborg University Hospital, respectively.
HIV-1 load was quantified using a commercial PCR assay
(RealTime HIV-1; Abbott Laboratories) using automated
extraction system (m2000 Real Time System; Abbott Labora-
tories). Viral RNA was amplified on the m2000rt platform
(Abbott Laboratories). CRP was measured in serum using an
immunoturbidimetric assay (HORIBA ABX A11A01611; Horiba
Ltd) for Pentra 400 (HORIBA ABC; Horiba Ltd). The results are
given in mg/l, and the precision of the assay was 8·3 CV% based
on repeated measurements of a normal serum sample in each
run (mean 0·71 (SD 0·06)mg/l).
Total serum 25(OH)D (D2 +D3) was quantified using a che-
miluminescence immunoassay (LIAISON code 310600) for
DiaSorin Liaison® and expressed as nmol/l. The accuracy of the
assay was monitored by participating in a Danish national
quality control programme for clinical laboratories as well as
running kit-specific high and low controls (LIAISON code
310601). Serum 25(OH)D< 25, 25–50 and >50 nmol/l were
defined as vitamin D deficiency, insufficiency and normal,
respectively.
Statistical analysis
Descriptive characteristics of continuous and categorical vari-
ables are summarised as medians (interquartile range (IQR))
and percentages, respectively. Demographic and clinical
characteristics were compared between HIV-positive and
HIV-negative individuals using Wilcoxon’s rank-sum test or
Pearson’s χ2 test, as appropriate. Linear mixed models were
used to investigate the relationships between 25(OH)D levels
with socio-demographic characteristics (sex, age, religion,
occupation and food security status), clinical parameters (HIV
status, BMI, WHO stage, viral load, CD4 count and CRP),
nutritional intervention and type of ART regimen. Season was
classified into four categories on the basis of rainfall – that is,
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harvest (September–November), light rain (December–
February), dry (March–May) and heavy rain seasons (June–
August) with the dry season being the most sunny time of the
year. As data were collected over 3 years, seasonal differences
between years were adjusted for using season-year random
effects and were included to capture changes in climatic
conditions. Normal probability and residual plots were used for
model checking. Variables with skewed distributions such as
HIV RNA and serum 25(OH)D were logarithm transformed
before analysis, and the results are reported after back-
transformation. Stata version 11.2 (StataCorp LP) was used for
all analyses.
Ethical consideration
Written informed consent was obtained from all the partici-
pants. Individuals randomised to no supplementation in the first
3 months were provided the nutritional supplement in the
subsequent 3 months. Patients who were excluded because of
severe acute malnutrition were referred to standard treatment
according to national guidelines(18). Ethics approval was
obtained from the Ethiopian National Health Research Ethical
Review Committee and Jimma University Ethical Review
committee. A consultative approval was obtained from the
Danish National Committee on Biomedical Research Ethics.
Results
A total of 348 HIV-positive persons were included in the trial,
whereas the HIV-negative reference group comprised 100
persons. The median age of HIV-positive and HIV-negative
persons was 30 (IQR 27; 38) and 29 (IQR 23; 37) years,
respectively. HIV-positive patients had lower levels of educa-
tion (P< 0·001), lower median BMI (18·8 v. 20·5 kg/m2,
P< 0·001) and were more food insecure (P< 0·001) compared
with HIV-negative persons (Table 1).
The median serum 25(OH)D level was 40·8 (IQR 29·0;
53·4) nmol/l with 16·7 and 52·3% having deficient and insuffi-
cient levels, respectively. The median baseline serum 25(OH)D
levels were higher in HIV-positive than in HIV-negative persons
(42·5 v. 35·3 nmol/l, P< 0·001). Moreover, 64% of HIV-positive
and 84% of HIV-negative persons had serum 25(OH)D< 50
nmol/l (P< 0·001).
Factors associated with serum 25-hydroxyvitamin D at the
time of initiating antiretroviral treatment
In a mixed model including HIV status, sex, age, religion,
occupation and food insecurity and after controlling for random
effects of season-year, HIV-positive patients had 17% (95% CI 6,
33%) higher serum 25(OH)D than HIV-negative persons.
Females had 24% (95% CI 16, 31%) lower serum 25(OH)D than
males, and Muslims had 12% (95% CI 5, 19%) lower serum
25(OH)D than Christians. The age groups 35–45 and >45 years
had 12% (95% CI 1, 22%) and 18% (95% CI 4, 30%) lower
serum 25(OH)D, respectively, than the age group 18–25 years.
Farmers and daily labourers had 37% (95% CI 11, 70%) and
17% (95% CI 3, 33%) higher serum 25(OH)D, respectively, than
persons who had governmental jobs. Serum 25(OH)D was not
associated with the level of food insecurity (Table 2).
As there were interactions between sex and religion and sex
and occupation, we further analysed stratifying by sex. In
males, there was no significant difference in serum 25(OH)D
between HIV-positive and HIV-negative persons, religion and
different age groups (P> 0·5). However, male farmers and daily
labourers had 44% (95% CI 7, 95%) and 20% (95% CI −2,
47%), respectively, higher serum 25(OH)D than male
participants who had governmental jobs. Moreover, male
participants with moderate food insecurity had 32% (95% CI
5, 67%) higher serum 25(OH)D than participants with no
food insecurity. HIV-positive females had 26% (95% CI 8, 47%)
higher serum 25(OH)D than HIV-negative females, and
Muslims had 15% (95% CI 7, 23%) lower values compared
with Christians. No differences in serum 25(OH)D were seen
between the age groups, occupation and status of food
insecurity in females (P> 0·5) (Table 2).
Table 1. Characteristics of 342 HIV-positive study participants and a
healthy reference group of 100 HIV-negative persons
(Numbers and percentages; medians and interquartile ranges (IQR))
HIV positive HIV negative
n % n % P
Age (years) 0·03
Median 30 29
IQR 27, 38 23, 37
Sex 0·45
Males 113 33·0 29 29·0
Females 229 67·0 71 71·0
Religion 0·07
Christian 213 62·3 72 72·0
Muslim 129 37·7 28 28·0
Educational status <0·001
No formal education 99 29·0 5 5·0
Some primary school 139 40·6 22 22·0
Completed primary school 33 9·7 10 10·0
Secondary school 62 18·1 40 40·0
Higher education 9 2·6 23 23·0
Food insecurity <0·001
No 44 12·9 33 33·0
Mild 68 19·9 28 28·0
Moderate 98 28·6 27 27·0
Severe 132 38·6 12 12·0
BMI (kg/m2) <0·001
Median 18·8 20·5
IQR 17·4, 20·6 18·6, 23·6
C-reactive protein (mg/l) <0·001
Median 2 0·5
IQR 0·5, 7·6 0·2, 2·5
CD4 count (cells/µl)
Median 182 – –
IQR 114, 241
Viral load (log) (copies + 1/ml)
Median 4·8 – –
IQR 4·3, 5·3
Serum 25(OH)D (nmol/l) <0·001
Median 42·5 35·3
IQR 31·6, 56·4 25·2, 44·9
<25 50 14·6 24 24·0 0·001
25–50 171 50·0 60 60·0
>50 121 35·4 16 16·0
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We assessed the association of the clinical parameters of
HIV patients at baseline with serum 25(OH)D level using a
mixed model adjusting for fixed effects of variables associated
with baseline serum 25(OH)D (Table 2), as well as for the
random effect of season-year. HIV-positive persons with WHO
stage IV at baseline had 17% (95% CI 1, 30%) lower 25(OH)D
level compared with WHO stage I, and participants on
TB treatment had 14% (95% CI 1, 26%) lower 25(OH)D
level than participants with no TB. We found no association
between serum 25(OH)D and CRP, viral load or CD4 count
(Table 3).
Effect of supplementation
A total of 282 study participants with BMI> 17 kg/m2 were
randomised to either the supplemented (n 189) or the non-
supplemented group (n 93) during the first 3 months. Of these,
baseline 25(OH)D was available for 186 participants with
BMI> 17 kg/m2 who received LNS and for ninety participants
who did not receive LNS during the first 3 months of ART. We
found no major differences between these two groups regarding
demographic or baseline clinical characteristics, ART regimen
initiation and baseline serum 25(OH)D level. Of 276 participants
who had baseline 25(OH)D data, 249 (90%) completed the
3-month follow-up visit, with 89% in the supplemented group and
Table 2. Factors associated with baseline serum 25-hydroxyvitamin D level in 342 HIV-positive and 100 HIV-negative persons
(Percentage differences β and 95 % confidence intervals)
Overall (n 442) Male (n 142) Female (n 300)
Variables β* 95% CI P* β* 95% CI P* β* 95% CI P*
HIV status
Negative – – –
Positive 17 5, 31 0·006 6 −13, 28 0·57 26 8, 47 0·003
Age (years)
18–25 – – –
25–35 −8 −17, 1 0·1 −9 −40, 38 0·66 −9 −18, 1 0·06
36–45 −12 −22, −1 0·04 −14 −43, 31 0·49 −9 −21, 4 0·17
>45 −18 −30, −4 0·02 −21 −49, 24 0·31 −13 −29, 8 0·20
Religion
Christian – – –
Muslim −12 −19, −5 0·001 −5 −18, 10 0·48 −15 −23, −7 0·001
Occupation
Governmental jobs – – –
Farmer 37 11, 70 0·004 44 7, 95 0·02 15 −7, 58 0·4
Housewife 2 −12, 17 0·83 – – −3 −18, 15 0·75
Private jobs −8 −21, 8 0·32 −12 −43, 12 0·2 −6 −22, 13 0·51
Small-scale trader 7 −7, 23 0·35 4 −15, 28 0·67 6 −14, 31 0·57
Daily labourer 17 3, 33 0·02 20 −2, 47 0·07 9 −9, 31 0·35
Student 5 −17, 34 0·67 – – 8 −15, 38 0·53
Unemployed −2 −15, 13 0·79 −6 −29, 25 0·68 – –
Food insecurity
No – – –
Mild 7 −5, 21 0·24 21 −5, −46 0·13 2 −11, 17 0·72
Moderate 6 −5, 19 0·32 32 5, 67 0·02 −4 −16, 9 0·52
Severe 8 −4, 22 0·18 18 −6, 49 0·16 6 −8, 21 0·43
Sex
Male – – – – –
Female −24 −31, −16 <0·001 – – – –
* Values are adjusted for all variables in the table as fixed effects with season-year as the random effect.
Table 3. Clinical factors associated with baseline serum
25-hydroxyvitamin D level in 342 HIV-positive persons at antiretroviral
treatment initiation
(Values are percentage difference β and 95% confidence intervals and
P value)
n β* 95% CI P*
BMI (kg/m2)
<18·5 157 −8 −16, 0·1 0·06
18·5–25 176 –
>25 9 12 −15, 48 0·43
On tuberculosis treatment
No 306 –
Yes 35 −14 −26, −1 0·04
WHO stage
I 100 –
II 102 −2 −13, 9 0·69
III 110 −4 −14, 8 0·49
IV 29 −17 −30, −1 0·04
CD4 count (cells/µl)
<100 130 −7 −17, 4 0·21
100–200 133 3 −6, 14 0·52
>200 74 –
Viral load (log) (copies + 1/ml) 338 0 −5, 4 0·92
C-reactive protein (mg/l)
<2 170 –
2–5 60 8 −4, 22 0·22
>5 112 −4 −13, 7 0·48
* Adjusted for sex, age, occupation and religion as fixed effect and for season-year as
random effect.
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92% in the non-supplemented group(14). A total of fifty-one (29%)
participants had ‘poor adherence’, which was defined as intake of
LNS<75%. The supplemented group had a 4·1 (95% CI 1·7,
6·4) nmol/l increase in serum 25(OH)D level, whereas the non-
supplemented group had a 10·8 (95% CI 7·8, 13·9) nmol/l
decrease at the 3rd month (Fig. 1).
To further understand these differences, we explored the role
of fat mass changes. The median fat mass change in the sup-
plemented group and the non-supplemented group was 1·73
(IQR 0·18; 3·6) kg and 0·52 (IQR −0·87; 1·75) kg, respectively.
No association was found between change in fat mass and
change in serum 25(OH)D (data not shown).
In a mixed model adjusting for baseline serum 25(OH)D,
change in fat mass and fat-free mass and for variables shown to
influence baseline 25(OH)D (Tables 2 and 3), the supple-
mented group had 43% (95% CI 31, 55%) higher serum
25(OH)D than the non-supplemented group at 3 months
(Table 4). Females had 16% (95% CI 7, 23%) lower serum
25(OH)D than males. Participants who received TDF/3TC/EFV
and zidovudine (AZT)/3TC/NVP treatment regimens had 14%
(95% CI 2, 25%) and 15% (95% CI 1, 28%), respectively, lower
serum 25(OH)D than participants who had been initiated with
the TDF/3TC/NVP regimen. However, no difference was found
when we classified ART regimens as efavirenz- and nevirapine-
based regimen or tenofovir- and non-tenofovir-based regimen
(data not shown). Serum 25(OH)D declined in both supple-
mented and non-supplemented participants with higher
baseline serum 25(OH)D (Fig. 2). The overall median change in
serum 25(OH)D was 10·1 (95% CI 3·48, 20), −0·5 (95% CI −2·51,
2·01) and −7·25 (95% CI −12·46, −3·78) for participants with
baseline serum 25(OH)D level <25, 25–50 and >50nmol/l,
respectively.
Discussion
The classical effects of low vitamin D status are rickets and
osteomalacia, but current evidence suggests that low serum
25(OH)D is also linked to other health consequences such
as diabetes, cancer and susceptibility to infections(1). In HIV-
positive patients, low vitamin D has been associated with
clinical disease progression, treatment failure and mortality(7–9).
The present study shows a low serum 25(OH)D in both HIV-
positive and HIV-negative individuals in Ethiopia. Moreover,
further reduction in serum 25(OH)D was observed after
ART initiation in HIV patients who did not receive vitamin
D-enriched nutritional supplementation.
In this study, farmers and daily labourers who were assumed to
be exposed to sunlight had better vitamin D status; Muslims had
lower vitamin D status than Christians. However, when we
stratified by sex, we found an association with occupation only in
males and with religion only in females. The latter finding may be
because of the use of more covering clothes by female Muslims,
which may reduce their sun exposure. In line with this, a study
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Fig. 1. Baseline and 3rd-month 25-hydroxyvitamin D (25(OH)D) levels by supplementation group. , Baseline 25(OH)D (nmol/l); , 3rd month 25(OH)D (nmol/l).
Table 4. Factors associated with serum 25-hydroxyvitamin D level after
3 months of nutritional supplementation and antiretroviral treatment
among 282 HIV-positive persons
(Values are percentage difference β and 95% confidence intervals and
P value)
β* 95% CI P*
Supplementation
No –
Yes 43 31, 55 <0·001
Antiretroviral treatment
TDF/3TC/NVP –
TDF/3TC/EFV −14 −25, −2 0·02
AZT/3TC/NVP −15 −28, −1 0·04
Other −16 −34, 7 0·15
Isoniazid prophylaxis
No –
Yes −1 −13, 12 0·81
TDF, tenofovir-DF; 3TC, lamivudine; NVP, nevirapine; EFV, efavirenz; AZT,
zidovudine.
* Values are with each variable adjusted for age, sex, religion, occupation, baseline
tuberculosis treatment, baseline serum 25(OH)D, change in fat mass and fat-free
mass and all variables in the table as fixed effect and season-year at 3 months as
the random effect.
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from Germany has shown that Turkish females with more
covering clothes had lower vitamin D levels than Turkish females
with conventional clothing(19). Thus, even when there is
abundant sunshine, the extent of UVB skin exposure depends
on clothing, living and working environments(1).
There was no association between food security level and
vitamin D status in females, whereas in males moderate food
insecurity was associated with better vitamin D status. This may
indicate that food is not the main source of vitamin D as
reported among pregnant women in southern Ethiopia(20).
Therefore, the high prevalence of vitamin D deficiency and
insufficiency in both HIV-positive and HIV-negative individuals
in Ethiopia may be due to the combined effect of low sun
exposure and low consumption of vitamin D-rich foods.
A number of studies have reported high proportion of
vitamin D deficiency and insufficiency in HIV-positive
patients(2,5,21–23). However, studies that compared vitamin D
status of HIV-positive patients with HIV-negative controls or the
general population have reported higher serum 25(OH)D in
HIV-positive compared with HIV-negative persons(4,10,11).
Higher serum 25(OH)D has also been reported in patients with
TB when compared with healthy controls(24). We also found
that HIV-positive patients had considerably higher serum
25(OH)D than HIV-negative individuals. When we stratified the
analysis by sex, this association remained only in females.
However, we found no interaction between HIV status and sex,
and the absence of an association in males may be due to small
number of male participants in our study. Previous studies have
reported that HIV associated weight loss mainly consist of fat
mass loss(25–27). Studies have also documented that females
lose disproportionately more fat than males during HIV infec-
tion(28–30). As vitamin D is stored in adipose tissue, an increase in
serum 25(OH)D due to HIV-associated fat mass loss may have
contributed to the higher level of vitamin D in antiretroviral-naive
HIV patients compared with the HIV-negative controls. How-
ever, we cannot confidently exclude residual confounding by
season, even though we adjusted our analyses for this.
We found that individuals with WHO clinical stage IV and
those who were on TB treatment at ART initiation had lower
serum 25(OH)D, but serum 25(OH)D was not associated with
CD4 count, viral load and serum CRP. The lower serum 25(OH)D
in patients with WHO clinical stage IV disease and TB may
be due to the reduced dietary vitamin D intake because of the
disease itself and/or due to reduced exposure to sun because of
their reduced mobility or hospitalisation. Moreover, drugs used
for TB treatment such as isoniazid and rifampicin may have
contributed to the reduction in serum 25(OH)D, because of their
direct biological effects on the metabolism of vitamin D(31).
Serum 25(OH)D increased slightly in the supplemented
patients, and declined in those not given a supplement. Other
studies among HIV patients have also shown an increase in
serum 25(OH)D with vitamin D supplementation(12,13,32,33).
Longitudinal studies in HIV patients without vitamin D sup-
plementation(34,35) have reported a decrease in serum 25(OH)D
with ART initiation as observed in our study. The decline in
serum 25(OH)D in the absence of supplementation may be due
to sequestration of vitamin D during gain in fat mass observed
with ART initiation(14). We found that patients with higher
serum 25(OH)D (>50 nmol/l) at baseline had a larger
decline, whereas supplemented patients with lower 25(OH)D
(<25nmol/l) at baseline had a larger increase in serum 25(OH)D
at 3 months. This may be due to regression to the mean, or
may suggest that patients who had higher 25(OH)D levels
at baseline may be affected more by the fat mass change, whereas
those with low serum 25(OH)D may have benefited more from
the supplementation.
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Fig. 2. Change in serum 25-hydroxyvitamin D (25(OH)D) from baseline to 3 months by baseline 25(OH)D level and supplementation group.
Vitamin D supplementation in HIV patients 1725
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114516003743
Downloaded from https://www.cambridge.org/core. Aalborg University Library, on 22 Feb 2018 at 10:51:41, subject to the Cambridge Core terms of use, available at
ART has been associated with vitamin D deficiency in HIV
patients(2,6,36–39). All patients in this study received a combina-
tion of non-nucleoside RT inhibitors and nucleoside RT
inhibitors. Patients who were treated with a combination of
TDF/3TC/EFV and AZT/3TC/NVP had lower serum 25(OH)D at
3 months compared with patients on TDF/3TC/NVP. Several
studies have reported an association between efavirenz and
vitamin D deficiency(2,35,37,40,41). In the MONET trial, which
was conducted among European HIV-positive adults on ART,
efavirenz and zidovudine were associated with vitamin D
deficiency. Moreover, an increase in vitamin D level was noted
when study participants in the MONET trial were changed from
efavirenz or zidovudine(42). Although the exact mechanism on
how efavirenz affects vitamin D metabolism is not well known,
it is hypothesised to be related to its effect on increased
catabolism of 25(OH)D through induction of the cytochromes
(CYP450, CYPA4, CYP24 and CYP2C9)(36,40,41,43).
This study investigated early changes in serum 25(OH)D
levels in HIV patients initiating ART and the effect of nutritional
supplementation in adult HIV patients. This has not been
reported in other studies in Africa or elsewhere in the tropics. In
addition, we have found and demonstrated a high occurrence
of low levels of serum 25(OH)D in people living in the tropics.
However, our study has some limitations. The HIV-negative
reference group was recruited over a short period of time and
mainly after recruitment of participants for the trial, whereas
HIV-positive participants were recruited over a 2-year time
period. We also found differences in serum 25(OH)D level
between the same seasons of different years, which we, how-
ever, controlled for by analysing season-year as a random
effect. We were not able to assess the effect of supplementation
on serum 25(OH)D among those with BMI< 17 kg/m2, as
those with BMI between 16 and 17 kg/m2 were not randomised
to delayed supplementation, and those with BMI<16 kg/m2
were not included in the trial. As very few patients had switched
ART regimen in the 3 months(44), our analyses are based on
the ART regimen used at initiation, and also the influence of
ART could not be analysed in details because of a very
uneven distribution of regimens and the use of second-line
drugs by indication.
Conclusion
Our results demonstrated low levels of serum 25(OH)D in both
HIV-positive and HIV-negative individuals in Ethiopia. Female
participants, males with presumed low sun exposure, and
participants with low BMI, WHO clinical stage IV disease and
on TB treatment were at higher risk of low serum 25(OH)D.
Moreover, further reduction in serum 25(OH)D after 3 months
of ART was observed in HIV patients who did not receive
nutritional supplement. We suggest that the changes in body
composition in HIV patients that result from HIV itself
before ART and from antiretroviral drugs after ART may
contribute to the early change in serum 25(OH)D. Public
awareness about the importance of sun exposure is necessary
to improve serum 25(OH) levels. Vitamin D replenishment
may be needed to prevent reduction in serum 25(OH)D level
during ART.
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